A persistent problem remains a challenge in HFpEF – patient heterogeneity.

We need the right patients for the right treatment, but how do we get it to them? We believe that one approach to solving this problem is to improve patient segregation and endotyping.

 



In collaboration with Bristol Myers Squibb and University of Pennsylvania, we recently identified a subset of patients at a very high risk of adverse outcomes, all characterized by increased fibroblast activity. Using our PRO-C6 biomarker assay we can accurately quantify this risk profile and differentiate patients based on how likely they are to be re-hospitalized or have all-cause mortality due to heart failure.

These findings were recently published in NEJM Evidence.

So how do we deal with patient heterogeneity?

We believe it is time to give physicians and clinicians a better tool than what is available now.

This is endotrophin endotyping, heart failure risk stratification redefined.

Please don't hesitate to contact us if you have any questions or other inquiries.

Please don't hesitate to contact us if you have any questions or other inquiries.